Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
RA DeFronzo, WB Reeves, AS Awad - Nature Reviews Nephrology, 2021 - nature.com
Diabetic kidney disease is the leading cause of kidney failure worldwide; in the USA, it
accounts for over 50% of individuals entering dialysis or transplant programmes. Unlike …
accounts for over 50% of individuals entering dialysis or transplant programmes. Unlike …
Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity
G Jia, MA Hill, JR Sowers - Circulation research, 2018 - Am Heart Assoc
Heart failure and related morbidity and mortality are increasing at an alarming rate, in large
part, because of increases in aging, obesity, and diabetes mellitus. The clinical outcomes …
part, because of increases in aging, obesity, and diabetes mellitus. The clinical outcomes …
Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action
Importance Only 1 class of glucose-lowering agents—sodium-glucose cotransporter 2
(SGLT2) inhibitors—has been reported to decrease the risk of cardiovascular events …
(SGLT2) inhibitors—has been reported to decrease the risk of cardiovascular events …
Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced …
Background Diabetes mellitus is an important risk factor for atrial fibrillation (AF)
development. Sodium–glucose co-transporter-2 (SGLT-2) inhibitors are used for the …
development. Sodium–glucose co-transporter-2 (SGLT-2) inhibitors are used for the …
Empagliflozin directly improves diastolic function in human heart failure
S Pabel, S Wagner, H Bollenberg… - European journal of …, 2018 - Wiley Online Library
Aims Empagliflozin, a clinically used oral antidiabetic drug that inhibits the sodium‐
dependent glucose co‐transporter 2, has recently been evaluated for its cardiovascular …
dependent glucose co‐transporter 2, has recently been evaluated for its cardiovascular …
SGLT2 inhibitors and their mode of action in heart failure—has the mystery been unravelled?
S Pabel, N Hamdani, M Luedde, S Sossalla - Current heart failure reports, 2021 - Springer
Purpose of review SGLT2 inhibitors (SGLT2i) are new drugs for patients with heart failure
(HF) irrespective of diabetes. However, the mechanisms of SGLT2i in HF remain elusive …
(HF) irrespective of diabetes. However, the mechanisms of SGLT2i in HF remain elusive …
Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure
M Packer - Circulation, 2017 - Am Heart Assoc
The mechanisms underlying the progression of diabetes mellitus and heart failure are
closely intertwined, such that worsening of one condition is frequently accompanied by …
closely intertwined, such that worsening of one condition is frequently accompanied by …
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
E Ferrannini, A Solini - Nature Reviews Endocrinology, 2012 - nature.com
This Review covers the rationale, physiological consequences and clinical application of
pharmacological sodium–glucose cotransporter 2 (SGLT2) inhibition. In patients with type 2 …
pharmacological sodium–glucose cotransporter 2 (SGLT2) inhibition. In patients with type 2 …
Empagliflozin reduces Ca/calmodulin‐dependent kinase II activity in isolated ventricular cardiomyocytes
J Mustroph, O Wagemann, CM Lücht, M Trum… - ESC heart …, 2018 - Wiley Online Library
Abstract Aims The EMPA‐REG OUTCOME study showed reduced mortality and
hospitalization due to heart failure (HF) in diabetic patients treated with empagliflozin …
hospitalization due to heart failure (HF) in diabetic patients treated with empagliflozin …
Localizations of Na+-d-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart
I Vrhovac, D Balen Eror, D Klessen, C Burger… - … -European Journal of …, 2015 - Springer
Novel affinity-purified antibodies against human SGLT1 (hSGLT1) and SGLT2 (hSGLT2)
were used to localize hSGLT2 in human kidney and hSGLT1 in human kidney, small …
were used to localize hSGLT2 in human kidney and hSGLT1 in human kidney, small …